Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing

NCT04830709 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04830709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04830709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
June 15, 2021
Completion date
March 31, 2033
Enrollment
752 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer